Sensitivity to temozolomide in brain tumor initiating cells
Open Access
- 13 April 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 12 (7), 756-760
- https://doi.org/10.1093/neuonc/noq032
Abstract
Molecular alterations in glioblastoma have the potential to guide treatment. Here, we explore the relationship between temozolomide (TMZ) response and O6-methylguanine DNA methyltransferase (MGMT) status in brain tumor initiating cells (BTICs). Methylation, expression, and sensitivity were assessed in 20 lines; associations were evaluated by Fisher's exact test. Some BTICs were sensitive. Sensitivity to TMZ was only associated with protein expression (P = .001). There were atypical BTICs including TMZ-resistant lines in which the methylation-specific PCR reaction revealed both methylated and unmethylated bands. BTICs are not uniformly resistant to TMZ; some are sensitive. MGMT status does not predict TMZ response with high precision.Keywords
This publication has 19 references indexed in Scilit:
- Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomasNeuro-Oncology, 2009
- MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide ResistanceClinical Cancer Research, 2009
- Proliferation of Human Glioblastoma Stem Cells Occurs Independently of Exogenous MitogensThe International Journal of Cell Cloning, 2009
- Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft modelJournal of Neuro-Oncology, 2008
- Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature, 2008
- Anti‐O6‐Methylguanine‐Methyltransferase (MGMT) Immunohistochemistry in Glioblastoma Multiforme: Observer Variability and Lack of Association with Patient Survival Impede Its Use as Clinical Biomarker*Brain Pathology, 2008
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma PatientsClinical Cancer Research, 2004
- Generation of Neurons and Astrocytes from Isolated Cells of the Adult Mammalian Central Nervous SystemScience, 1992